Hepatopancreaticobiliary tumours are often diagnosed at an advanced disease stage, in which encasement or invasion of local biliary or vascular structures has already occurred. Irreversible electroporation (IRE) is an image-guided tumour ablation technique that induces cell death by exposing the tumour to high-voltage electrical pulses. The cellular membrane is disrupted, while sparing the extracellular matrix of critical tubular structures. The preservation of tissue integrity makes IRE an attractive treatment option for tumours in the vicinity of vital structures such as splanchnic blood vessels and major bile ducts. This article reviews current data and discusses future trends of IRE for hepatopancreaticobiliary tumours.
Hepatopancreaticobiliary (HPB) tumours are typically and insidiously characterized by a lack of symptoms, preventing prompt diagnosis, and by rapid local progression, leading to encasement or invasion of local biliary and vascular structures. This precludes safe curative-intent surgery in the majority of patients with pancreaticobiliary tumours [1] .
For early stage hepatocellular carcinoma and small colorectal liver metastases (CRLMs) thermal ablative therapies, such as radiofrequency ablation and microwave ablation, are nowadays widely accepted treatment options [2] . Nonetheless, thermal ablation is frequently contraindicated because of the risk of collateral damage to biliary, vascular or other heat-sensitive structures [2] . In addition, thermal ablation is less effective in proximity to major blood vessels because heat is lost to the flowing blood; a phenomenon known as the heat-sink effect [2] .
The outcome of palliative chemotherapy or radiotherapy for pancreaticobiliary tumours remains highly unsatisfactory, with median overall survival (OS) rates of 6-10 months for locally advanced pancreatic cancer (LAPC) and 3-6 months for unresectable cholangiocarcinoma [3, 4] .
The paucity of effective treatment options has led to the search for new techniques to treat locally advanced disease.
A relatively novel ablation technique that holds promise for these difficult-to-reach tumours is irreversible electroporation (IRE) . In contrast to other ablation techniques, the working mechanism of IRE is predominantly nonthermal [5] . It uses electric pulses to create nanopores in the cell membrane of the tumour cell, eventually causing the cell to undergo apoptosis [6] . As the effect of IRE is confined to the cell membrane, the surrounding extracellular matrix structures are unaffected [6] .
Indeed, the cellular constituents of surrounding and traversing structures such as vascular and biliary endothelial cells will be irreversibly damaged, similar to the target tissue. However, the preservation of the extracellular matrix constituting the structural and functional integrity of these vascular and biliary tubular structures, allows for fast tissue regeneration [6] . This makes IRE a theoretically safe treatment option for tumours in the vicinity of major bile ducts and splanchnic blood vessels.
Here we review the available clinical data and discuss future trends of IRE for HPB tumours that are not amenable for surgery or other ablation techniques due to their proximity to vascular, biliary, and intestinal structures. The general application of IRE will be described after which application for treatment of liver, pancreatic, and biliary tumours will be separately discussed.
Irreversible Electroporation

Working Mechanism
Depending on the magnitude of the electric field and its exposure time, pulsed electric fields (PEFs) provoke either temporary (reversible) permeabilization of cell membranes or permanent (irreversible) membrane disruption resulting in cell death [5] . The formation of temporary nanopores allows genes (electrogenotherapy) and drugs (electrochemotherapy) to transfer into cells that normally would not be able to penetrate the cell membrane. In clinical practice, the best known example of reversible electroporation is electrochemotherapy, such as injection of bleomycin before electroporation for the treatment of skin cancer [7] .
When the PEFs exceed a certain threshold value (w650 V/cm) irreversible injury to the membranes of all cells within the ablation zone will lead to massive apoptosis that eventually evolves in fibrotic scar tissue at macroscopic level (IRE) [5] .
Patient Selection
All patients should be discussed in a multidisciplinary team that, at least, consists of a diagnostic and interventional radiologist, an HPB surgeon, a medical and radiation oncologist, and a gastroenterologist. Patients should be evaluated in a preprocedural workup, including cardiac screening and full anesthetic review. Patients with poor functional reserve (American Society of Anesthesiologists score >3) should not be considered suitable candidates.
The increased cell membrane permeability caused by PEFs opens a path for ion transport, which can induce cardiac arrhythmias and defibrillation. In the milliseconds lasting time frame after cardiac contraction (ie, following the R-wave), the cardiac muscle is absolutely refractory to electrical stimuli. By synchronized pulse delivery within the refractory period of the heart, the risk of cardiac arrhythmias is reduced [8] . As the delivery of PEFs cannot be synchronized with cardiac R waves in patients with ventricular cardiac arrhythmias, this is considered an absolute contraindication for IRE. Although epilepsy is still listed as an absolute contraindication for IRE, the presumption that PEFs may evoke seizures by electrical discharges in the brain seems precipitated. Nielsen et al [9] , who investigated signal alterations on electroencephalography during clinical IRE, did not find a reactive cerebral response after the delivery of high-voltage electric pulses. Transmucosal tumour invasion into surrounding intestines or extensive involvement of the duodenum should also be considered an absolute contraindication due to the increased risk of perforation or ulceration [10] . Other contraindications include congestive heart failure (New York Heart Association functional class >II), uncontrolled hypertension, and any implanted cardiac stimulation devices. Coronary artery disease (ie, myocardial infarction <6 months), atrial fibrillation, the presence of metallic foreign objects in the ablation zone (eg, nonremovable self-expanding metal biliary stent, and treatment with chemo-or immunotherapy within 4 weeks before the procedure are considered relative contraindications.
The NanoKnife System
Currently, the only commercially available IRE system is the NanoKnife (AngioDynamics, Latham, NY) ( Figure 1 ). The system consists of a generator to which 6 monopolar 19-gauge probes can be connected. Furthermore, the AccuSync electrocardiogram-gating device (AccuSync Medical Research Corporation, Milford, CT) is connected to the generator and a 5-lead electrocardiogram, resulting in synchronized pulse delivery within the refractory period of the heart to prevent cardiac arrhythmias. The NanoKnife generator delivers electrical pulses through the active tips of the monopolar probes connected to the generator. The monopolar probes are 19-gauge needles, with an active tip that can be exposed between 0.5-4 cm with increments of 0.5 cm, depending on the depth of the lesion.
Procedure
Before the procedure, the exact size and geometric shape of the tumour is assessed to determine the number and configuration of the probes. Although a minimum of 2 probes is needed to create an ablation zone, multiple probes are often required to radically ablate the tumour including a tumour-free margin of at least 5 mm in all directions. IRE needs to be performed under general anesthesia. Complete muscle relaxation is mandatory to counteract the stimulation of skeletal muscle due to the electrical pulses delivered and to prevent movement of probes secondary to muscle contraction [9] . Before pulse delivery, complete muscle relaxation should be confirmed by establishing a train-of-four ratio of 0 [9] . It is recommended to connect the patient to an external defibrillator to allow rapid intervention in case of ventricular arrhythmias. IRE can be performed during open laparotomy using intraoperative ultrasound (US) or percutaneous using contrast-enhanced computed tomography (CECT) or US guidance. For the CT-guided approach, CT fluoroscopy is strongly recommended to allow dynamic and repetitive real-time visualization of the needle electrodes, the target lesion, and its surrounding structures. The probes should be inserted parallel to each other to promote homogenous energy delivery.
Transcatheter CT angiography, using an arterial flush catheter in the common hepatic artery (for hepatic IRE) or in the proximal abdominal aorta (for pancreatic IRE), reduces the required contrast dose (40 cm 3 contrast 1:1 diluted with saline for hepatic IRE and 80 cm 3 contrast 1:1 diluted with saline for pancreatic IRE per series) and improves accuracy at the cost of an additional intervening procedure ( After confirmation of correct probe placement, electroporation is performed between all electrode pairs that are separated between 1.2-2.4 cm from each other. Then, 10-20 test pulses of 1500 V/cm with a duration of 90 ms are delivered for each electrode pair to determine the delivered current. The target current should preferably lie between 20-40 A. Voltage settings are manually adjusted in case of pending over-or undercurrent. Subsequently, 70-90 additional pulses are administered for each electrode pair.
Liver
Centrally located liver lesions can be unsuitable for resection or thermal ablation due to their close proximity to the main bile ducts and portal vein. As IRE enables the preservation of these structures, it may prove particularly suitable for this indication.
Although there are no strict size criteria, IRE seems to be most effective for tumours 3 cm in diameter; beyond this size the lesion requires multiple overlapping ablations, resulting in a decrease in efficacy of IRE [12] .
Several studies investigating IRE for primary and secondary liver malignancies have been reported [13e33]. Scheffer et al [13] were the first to demonstrate the proof of principle that IRE could actually be used for the radical ablation of human tumours. In their ablate-and-resect study (COLDFIRE-1 [colorectal metastatic liver disease: feasibility of irreversible electroporation] trial) the ability of IRE to cause complete macroscopic tumour nonviability in colorectal liver metastases was validated using 5-triphenyl tetrazolium chloride vitality stain ( Figure 4 ) [13] .
Safety
A systematic review evaluating the safety of hepatic IRE in 129 patients (227 tumours), showed an overall complication rate of 16% [12] . No IRE-related deaths were reported after hepatic IRE. As with other needle-guided interventions, puncture-related complications (ie, pneumothorax and hemorrhage) are infrequently encountered. The applied electrical field can cause cardiac arrhythmias, but cardiac gating greatly reduces this risk. Deodhar et al [8] demonstrated that even when the needle electrodes were placed within the myocardium, no lasting dysrhythmias were seen when the electrical pulses were delivered in synchrony with the R-wave. Postprocedural pain seems to be similar to pain after thermal ablation, with comparable amounts of self-administered pain medication [34] . Percutaneous IRE can cause (transient) brachial plexus neuropraxia, due to the extended arm position required for CT scanning. Rarely, vessel-related complications occur (ie, [partial] portal vein thrombosis). Narayanan et al [23] investigated the effect of IRE on vessels in close proximity to the ablation zone in 101 patients (129 tumours). Abnormal vascular changes were seen in 7 of 158 vessels (4.4%). All changes were venous in origin, with the portal vein most commonly affected, probably due to flow dynamics within the portal venous system [23] . Although IRE is believed to be primarily nonthermal, experimental work demonstrated a significant rise in temperature, in particular immediately adjacent to the needle electrodes [35] . Occlusion of bile ducts has been reported after hepatic IRE, which may have been caused by thermal coagulation of the bile duct that was in direct contact with one of the needle electrodes [28] . Therefore, to avoid damage of thermally sensitive structures, it is recommended to place the needle electrodes at least 5 mm from bile ducts or large blood vessels [35] .
Efficacy
Efficacy results of hepatic IRE varies widely in current literature (ranges between 45.5%-100%), due to the heterogeneity of treated tumours and patient population [13e31]. Furthermore, physicians performing IRE were found to have a learning curve, with complication and recurrence rates plateauing after 100 cases [27] . This could imply that the reported efficacy rates will improve with maturing experience. An overview of the available data on efficacy of IRE for liver tumours is given in Table 1 . The results of the currently ongoing COLDFIRE-2 trial, a phase I/II safety and efficacy trial for centrally located CRLM (NCT02082782), are eagerly awaited [36] . One remarkable example from that trial shows the ability of IRE to control even large-sized liver tumours ( Figure 5 ).
Follow-Up
Much is still unknown about the imaging characteristics of liver lesions treated with IRE, resulting in lack of standardized follow-up regimens. Magnetic resonance imaging (MRI), CECT, and positron emission tomography CT are the most commonly used imaging modalities to monitor postablative liver lesions for remnant or recurrent disease. Sugimoto et al [37] assessed the diagnostic accuracy of contrast-enhanced US (CEUS), CECT, and gadoxetic acidenhanced MRI in identifying residual tumour tissue in the Perc. (28) Open (14) Lap. (2) HCC (14) CRLM (20) Other (10) 2 [18] 13 14 63 Perc. (7) Open (2) Lap. (4) HCC (5) CRLM (6) CCC (2) 1. [22] 28 65 51 Perc. (6) Open (22) HCC (2) CRLM (21) Other (5) 1 subacute follow-up (<1 week) of patients with malignant hepatic tumours treated by IRE. Their results suggested that CEUS was the ideal modality for evaluating the treatment response to IRE [37] .
Pancreas
Pancreatic adenocarcinoma is one of the most aggressive cancers, with an overall 5-year survival rate of <5% [3] . Although oncological outcome is best for patients with nonmetastatic resectable pancreatic cancer, cure is rarely achieved [39] . Due to an initial lack of symptoms, tumours are often diagnosed at an advanced stage and therefore only 15%-20% of patients are eligible for surgical resection [3] . Patients with LAPC (nonmetastatic, unresectable disease due to vascular encasement) are nowadays offered systemic chemotherapy with or without radiotherapy and have poor prognosis, with a median overall survival of 12 months [1] .
IRE plays a unique role in pancreatic cancer, as it can be used for primary tumour control as well as for margin accentuation in combination with resection for borderline resectable pancreatic tumours [40] . In the absence of studies directly comparing approach (open or percutaneous) and image-guidance technique (CT or US), the method of treatment should be based on the performing physician's preference and experience.
Safety
Complications related to the gastrointestinal (GI) tract are frequently encountered after pancreatic IRE, such as nausea, vomiting, diarrhea, delayed gastric emptying, loss of appetite, reduced intake, and abdominal pain [10,40e46] . Duodenal ulcers, perforation, or bleeding have also been described, especially when the intestine was directly adjacent to the ablation zone [10,41e43,46e48] . Therefore, transmucosal tumour invasion into the surrounding intestines is nowadays considered an absolute contraindication. After pancreatic IRE, there is most often an asymptomatic increase in amylase and lipase levels; however, clinical significant cases of pancreatitis have also been reported [10,43,45,46,48e50] . Although the vessel wall should remain intact owing to the sparing of collagenous structures, vessel-related complications do occur [10,40e44,46,48] . Most commonly these involve asymptomatic vessel narrowing caused by reactive spasms, showing full recovery in the weeks following IRE [10] . However, Scheffer et al [10] described a patient that experienced postprandial abdominal cramps after IRE, caused by a persistent near occlusion of the superior mesenteric artery. Portal vein thrombosis (complete or partial) is another vessel-related complication, which even can be fatal when the arterial supply to the liver is also compromised. Placement of a portal vein stent directly after the IRE procedure may be considered or indicated in patients with preexistent narrowing of the portal vein, to reduce the risk of an acute occlusion due to reactive oedema ( Figure 6 ). Complications to the biliary tree are infrequently encountered, including new-onset biliary obstruction or bile leakage [10,40e42,44,47,49] . In most patients undergoing hepatic IRE, a transient mild-to-moderate increase in blood pressure (20-45 mm Hg) is observed during pulse delivery. However, during pancreatic IRE severe increases are common [9] . It is hypothesized that this elevation in blood pressure is due to stimulation of the autonomous nervous system, either by direct stimulation or by pain perception, although the exact mechanism remains unclear [9] . As metal objects can distort the electric field distribution, resulting in an unpredictable ablation zone and heating of the metal, the manufacturer discourages performing IRE near metallic objects, such as stents. However, several centres have safely performed IRE with a metal stent within the ablation zone, including our own [51] .
In contrast to hepatic IRE, mortality related to pancreatic IRE has been described [40, 41, 44, 47, 48] . Kluger et al [41] reported 6 patients that died within 90 days after IRE, of which 3 were deemed IRE-related (1 upper GI bleeding and a portal vein thrombosis, 1 intraperitoneal hemorrhage requiring embolization of gastroduodenal artery and causing multisystem organ failure, and 1 duodenal and bile duct necrosis). Martin et al [40] experienced 3 deaths within 90 days after IRE, including a patient with an upper GI bleeding from an IRE-induced duodenal ulcer, a patient with liver failure in pre-existing complete portal vein thrombosis, and a pulmonary embolism.
Efficacy
Currently available results of efficacy and survival after pancreatic IRE have been obtained from several case series. The largest study, conducted by Martin et al [40] included 200 patients with LAPC treated with IRE using an open approach for primary local control (n ¼ 150) and for margin accentuation combined with resection (n ¼ 50). The study reported a median OS of 24.9 months from diagnosis. A more recently published study by Narayanan et al [46] reported a median OS of 27.0 months from diagnosis and 14.2 months from the time of IRE for primary local control. All patients (n ¼ 50) received chemotherapy before IRE and 3 patients underwent surgical resection as a result of down staging after IRE. Pathological examinations of all surgical specimens showed negative margins and complete (n ¼ 1) or partial (n ¼ 2) tumour necrosis. In the PANFIRE (Pancreatic Neoplasm and Feasibility study of Irreversible Electroporation) study, 25 patients with LAPC were treated with IRE for primary local control [10] . Median OS from diagnosis was 17.0 and 11.0 months from the time of IRE. A possible explanation for the shorter overall survival compared with the previously mentioned studies may be that only half of the patients (n ¼ 13 of 25) included in the PANFIRE study received chemotherapy before IRE. Neoadjuvant chemotherapy probably improves survival, but furthermore it filters out the patients with rapid disease progression who would not benefit from IRE treatment. An overview of all studies reporting survival results (excluding case reports) is given in Table 2 .
Follow-Up
Interpretation of the ablated area is difficult, particularly after pancreatic IRE, for various reasons. First of all the ablation zone is often ill-defined on MRI and especially on CT, as little healthy pancreatic parenchyma surrounds the tumour [52] . Also, the presence of oedema within the ablation zone impedes precise delineation of the ablation zone from surrounding healthy tissue [52] . The World Health Organization and Response Evaluation Criteria in Solid Tumors criteria depend on decrease in tumour size, although decrease in viable tumour mass is not always reflected by changes in tumour size, due to replacement of tumour tissue by fibrotic tissue [52] . Therefore, a preferable method of treatment evaluation of IRE is to combine tumour and ablation zone sizes with alterations in enhancement and diffusion. Vroomen et al [53] suggested superiority of DWI-b800 and CEMRI in detecting local recurrence: all 5 patients with local recurrence after pancreatic IRE showed DWI-b800 hyperintensity and low apparent diffusion coefficient values at the site of eventual recurrence at 6 weeks. 
Biliary Tract
Resection of perihilar cholangiocarcinoma (PHC) is the only potentially curative treatment, but only a small subset of patients have resectable disease at time of diagnosis (10%-20%) [54] . Unresectable cholangiocarcinoma, including both locally advanced disease and metastatic disease, has a poor prognosis, with median overall survival of 3-6 months [54] . As the safety and feasibility of IRE has been demonstrated in proximity of main bile ducts and large vascular structures, IRE could also be suitable to treat locally advanced PHC [23, 28] . This is defined as bilateral second-order biliary branch involvement, unilateral secondary biliary branch involvement with contralateral arterial or portal encasement, or N2 lymph nodes on imaging or during staging laparoscopy, all in the absence distant metastatic disease. IRE may also be considered for patients with late-onset resection-site recurrence (after 6 months).
Currently, literature on IRE in PHC is limited; however, data regarding safety of IRE for other perihilar liver malignancies have been described [22, 28] . Silk et al [28] treated 11 patients with hepatic metastases located within 1 cm of the common, left, or right hepatic duct. Three patients showed increase of the biliary duct dilation on CT, of which 1 patient required stent placement due to tumour progression. Kingham et al [22] treated 65 liver malignancies that were within 1 cm from a major hepatic vein or portal pedicle, showing patency of all hepatic veins and pedicles on postoperative imaging, except for 1 major vessel occlusion.
Melenhorst et al [51] described a case report of a patient with a Bismuth-Corlette stage IV unresectable cholangiocarcinoma treated successfully with percutaneous IRE. After delivery of all pulses, CT demonstrated patency of the portal vein and surrounding arteries and the intrahepatic bile ducts appeared unremarkable. The 4-, 6-, and 12-month follow-up CT showed no tumour progression or metastatic disease. Furthermore, a total of 6 patients have been treated in the VU University Medical Center with percutaneous IRE for locally advanced PHC (n ¼ 3), resection-site recurrence (n ¼ 2), and recurrence after intraarterial radioembolization (n ¼ 1) (Figure 7) . Three patients had a nonretrievable metal Wallstent (Boston Scientific, Marlborough, MA). Five patients experienced no IRErelated morbidity. One patient was readmitted after a few days presenting with liver abscesses requiring percutaneous drainage and 2 kissing stents were placed in the left and right biliary duct. After this period, the patient experienced multiple periods of cholangitis and bacteremia and eventually deceased 94 days after IRE. [55] . b Three patients were also included in an earlier report [50] . c Six patients experienced local recurrence (3%); however, 3 patients had unsuccessful ablation (total 4.5%). d Eleven patients were also included in an earlier report [45] .
As more data regarding the safety and efficacy of IRE in PHC are lacking, 2 academic hospitals in the Netherlands (VU University Medical Center and Academic Medical Center, Amsterdam) are currently collaborating in the ALPACA (ablation with irreversible electroporation in patients with advanced perihilar cholangiocarcinoma) trial, a prospective phase I/II trial for patients with locally advanced PHC or late-onset resection-site recurrence [58] .
Future Trends
Currently, clinical practice lacks properly validated tissueand tumour-specific standardized treatment protocols, as the recommended ablation protocol is mainly based on animal studies investigating the effect of IRE on healthy liver tissue. There is a potential flaw in the assumption that different organs will respond similarly to IRE. Furthermore, tumour histology also influences the electrical properties of the tissue [59] , not reflected in current uniformly applied treatment protocols for various tumour types. The search to identify the optimal ablation protocol for different tissue and tumour types with heterogeneous electrical properties is ongoing.
Another shortcoming of the technique is the absence of feasible intraprocedural endpoints that determine effective and complete ablation. With radiofrequency ablation, as tissue loses its ability to conduct current when it desiccates, a precipitous rise in impedance occurs (''roll-off''). This roll-off has been shown to be a significant predictor of local control [60] . Imaging directly after IRE is not feasible since the formation of oedema and gas pockets during IRE limits the physician's ability to accurately delineate the irreversible damaged ablation zone. Martin et al [61] suggested that a current increase of at least 12 A for each electrode pair would be a feasible endpoint. This suggestion is based on the postulation that increased current is a derivative of membrane permeabilization as this reduces resistance. Furthermore, they recommend repetition of the treatment protocol until the desired 12-A current change has been achieved. However, preclinical studies performing IRE in an acellular gel phantom have demonstrated a similar rise in amperage as well as a rise in temperature, refuting the theory of decreased resistance being the sole derivative of membrane permeabilization [35] . The authors hypothesized that a temperature rise during IRE co-contributes to the decreased resistance. Moreover, caution should be taken when repeating the electroporation protocol as the accumulated energy causes a higher temperature rise, which may cause thermal damage to healthy structures that lie in proximity to the ablation zone [38] . Hence, feasible endpoints for effective ablation still need to be established.
The current focus of several trials is the immunogenic potential of IRE, as the mechanism through which IRE operates also results in a systemic effect. Locally generated antitumour T-cell responses could eventually provide protection against tumour outgrowth of distant metastases, which could positively affect survival [62] . This immunologic response makes IRE attractive for combination with immunotherapeutic approaches treating patients both locally and systemically.
The combined therapy of IRE with chemotherapy is another multifaceted approach that may increase treatment effect. Directly after IRE, a zone of reversibly electroporated tissue lies adjacent to the ablation zone [13] . As stated previously, chemotherapeutics that normally cannot penetrate the cell membrane can now travel freely into the cells in this region. Elaborating on this principle, the combination of chemotherapy with IRE may eradicate the remnant viable tumour cells within that region, reducing the risk of local recurrence.
The electrical field distribution is highly dependent on precise probe placement. Optical or electromagnetic navigation may prove to represent helpful tools for exact electrode placement [63e65]. Moreover, a probe with 2 poles on a single needle (bipolar single-insertion device) is currently under development [66] . This would allow single as opposed to multiple needle placements, reducing procedure time and the risk on puncture-related complications.
Conclusions
Overall, based on current literature, IRE represents a promising technique with regard to safety and local control for HPB tumours ineligible for resection or thermal ablation due to their close proximity to vital structures. Nonetheless, it should be emphasized that serious complications including mortality, especially with pancreatic IRE, have been described. Most of the currently available data is based on noncomparative series from a relatively small group of key opinion leaders. The early results mandate and compel us to setup larger and high-quality controlled trials, required to further validate the additive value of IRE over the current standard of care. Currently ongoing studies are the CROSSFIRE (crossatlantic randomized controlled trial comparing outcome in survival after systemic plus focal therapy for inoperable pancreatic carcinoma: radiotherapy versus irreversible electroporation) trial, a randomized controlled phase III trial, comparing the outcome of IRE with stereotactic ablative body radiotherapy after induction chemotherapy on overall survival for patients with LAPC, and the ALPACA-trial, a controlled phase I/II study for patients with perihilar cholangiocarcinoma (Klatskin tumour). Furthermore, the authors are currently preparing the COLDFIRE-3 trial to compare IRE with MR-guided stereotactic ablative body radiotherapy for small CRLMs (<3 cm) unsuitable for surgical resection and thermal ablation and the PANFIRE-3 trial, a randomized controlled phase II trial comparing resection with or without IRE for margin accentuation. These and other studies will hopefully further define the exact role of IRE in the treatment of HPB tumours.
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